Deoxycytidine HCl | CAS# 3992-42-5 (HCl) | deoxyribonucleoside

MedKoo Cat#: 413537 | Name: Deoxycytidine HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Deoxycytidine HCl is the salt form of Deoxycytidine, a deoxyribonucleoside, a component of deoxyribonucleic acid. It is similar to the ribonucleoside cytidine, but with one hydroxyl group removed from the 2' position. Deoxycytidine can be phosphorylated by deoxycytidine kinase (DCK).

Chemical Structure

Deoxycytidine HCl

CAS#3992-42-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 413537

Name: Deoxycytidine HCl

CAS#: 3992-42-5 (HCl)

Chemical Formula: C9H14ClN3O4

Exact Mass: 0.0000

Molecular Weight: 263.68

Elemental Analysis: C, 41.00; H, 5.35; Cl, 13.44; N, 15.94; O, 24.27

Price and Availability

Size	Price	Availability	Quantity
1g	USD 250.00	2 Weeks
5g	USD 550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

3992-42-5 (HCl) 951-77-9 (free base)

Synonym

Deoxycytidine HCl; NSC83251; NSC-83251; NSC 83251

IUPAC/Chemical Name

4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one hydrochloride

InChi Key

LTKCXZGFJFAPLY-OERIEOFYSA-N

InChi Code

InChI=1S/C9H13N3O4.ClH/c10-7-1-2-12(9(15)11-7)8-3-5(14)6(4-13)16-8;/h1-2,5-6,8,13-14H,3-4H2,(H2,10,11,15);1H/t5-,6+,8+;/m0./s1

SMILES Code

NC1=NC(N([C@H]2C[C@@H]([C@H](O2)CO)O)C=C1)=O.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

2'-Deoxycytidine hydrochloride is composed of the purine nucleoside guanine linked by its N9 nitrogen to the C1 carbon of deoxyribose.

In vitro activity:

The results indicated that 5-Aza-CdR (5-aza-2’-deoxycytidine) can inhibit cell growth significantly versus control groups. As shown in Figure 1, all concentrations of 5-Aza-CdR5 inhibited cell growth significantly (P < 0.001). IC50 values for 5-Aza-CdR were obtained at 2.5 μM. Reference: Int J Prev Med. 2020 Sep 10;11:147. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643574/

In vivo activity:

The decrease of FoxP3 methylation after DAC (deoxycytidine HCl) treatment increased FoxP3 mRNA and restored the FOXP3-RORC axis in the mouse liver (Fig. 4A). Also, the imbalanced Treg/Th17 in the liver was reversed after DAC therapy (Fig. 4B, C). Interestingly, Treg and Th17 cells of the spleen or thymus were not different among groups (Fig. 4B). Reference: Int Immunopharmacol. 2021 Jul;96:107820. https://pubmed.ncbi.nlm.nih.gov/34162167/

	Solvent	mg/mL	mM
Solubility
	DMSO	3.0	11.38
	PBS (pH 7.2)	10.0	37.92
	Water	41.0	155.49

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 263.68 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Sanaei M, Kavoosi F. Effect of 5-aza-2'-deoxycytidine on Estrogen Receptor Alpha/Beta and DNA Methyltransferase 1 Genes Expression, Apoptosis Induction, and Cell Growth Prevention of the Colon Cancer HT 29 Cell Line. Int J Prev Med. 2020 Sep 10;11:147. doi: 10.4103/ijpvm.IJPVM_140_19. PMID: 33209217; PMCID: PMC7643574. 2. Jiang T, Zhang HW, Wen YP, Yin YS, Yang LH, Yang J, Lan T, Tang CW, Yu JK, Tai WL, Yang JH. 5-Aza-2-deoxycytidine alleviates the progression of primary biliary cholangitis by suppressing the FoxP3 methylation and promoting the Treg/Th17 balance. Int Immunopharmacol. 2021 Jul;96:107820. doi: 10.1016/j.intimp.2021.107820. Epub 2021 Jun 2. PMID: 34162167.

In vitro protocol:

In vivo protocol:

1. Jiang T, Zhang HW, Wen YP, Yin YS, Yang LH, Yang J, Lan T, Tang CW, Yu JK, Tai WL, Yang JH. 5-Aza-2-deoxycytidine alleviates the progression of primary biliary cholangitis by suppressing the FoxP3 methylation and promoting the Treg/Th17 balance. Int Immunopharmacol. 2021 Jul;96:107820. doi: 10.1016/j.intimp.2021.107820. Epub 2021 Jun 2. PMID: 34162167.

1: Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018 Jan 11;4(1):e173501. doi: 10.1001/jamaoncol.2017.3501. Epub 2018 Jan 11. PMID: 28973074; PMCID: PMC5833648. 2: Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26. PMID: 22285168. 3: Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr;17(4):500-3. doi: 10.1038/nm.2344. Epub 2011 Apr 3. PMID: 21460848; PMCID: PMC3755490. 4: Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016 May 3;315(17):1844-53. doi: 10.1001/jama.2016.4324. PMID: 27139057. 5: Karasic TB, O'Hara MH, Loaiza-Bonilla A, Reiss KA, Teitelbaum UR, Borazanci E, De Jesus-Acosta A, Redlinger C, Burrell JA, Laheru DA, Von Hoff DD, Amaravadi RK, Drebin JA, O'Dwyer PJ. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Jul 1;5(7):993-998. doi: 10.1001/jamaoncol.2019.0684. PMID: 31120501; PMCID: PMC6547080. 6: Zhong WZ, Chen KN, Chen C, Gu CD, Wang J, Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y, Xu L, Wang CL, Chen MW, Kang X, Yan W, Yan HH, Liao RQ, Yang JJ, Zhang XC, Zhou Q, Wu YL. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. J Clin Oncol. 2019 Sep 1;37(25):2235-2245. doi: 10.1200/JCO.19.00075. Epub 2019 Jun 13. PMID: 31194613. 7: de Santibañes M, Sanchez Clariá R, de Santibañes E, Pekolj J, Mazza O. Nuevos avances en el tratamiento del cáncer de páncreas localmente avanzado [New progress in the treatment of locally advance pancreatic cancer]. Medicina (B Aires). 2019;79(Spec 6/1):576-581. Spanish. PMID: 31864229. 8: Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960-6. doi: 10.1200/JCO.2006.07.9525. Epub 2007 Apr 23. PMID: 17452677. 9: Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23. PMID: 21783417. 10: Ionescu-Ittu R, Shang A, Velde NV, Guerin A, Lin Y, Shi L, Shi S, Qayum N. Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world. J Comp Eff Res. 2019 Oct;8(13):1067-1075. doi: 10.2217/cer-2019-0062. Epub 2019 Aug 27. PMID: 31452397.